We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+21.94%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$542M
AUM Growth
+$53.3M
Cap. Flow
-$63.4M
Cap. Flow %
-11.7%
Top 10 Hldgs %
49.87%
Holding
88
New
19
Increased
18
Reduced
25
Closed
23

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$13M
2
SRRK icon
Scholar Rock
SRRK
+$10.7M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$10.4M
4
PCVX icon
Vaxcyte
PCVX
+$9.43M
5
PFE icon
Pfizer
PFE
+$8.03M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$14.9M
2
VRNA
Verona Pharma
VRNA
+$13.9M
3
IRON icon
Disc Medicine
IRON
+$11.7M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$9.97M
5
WVE icon
Wave Life Sciences
WVE
+$8.49M

Sector Composition

Rank Sector Weight
1 Healthcare 90.1%
2 Miscellaneous 9.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
1
DELISTED
Merus
MRUS
$39M 7.2%
741,972
-69,049
-9% -$3.25M
AKRO
2
DELISTED
Akero Therapeutics
AKRO
$38.1M 7.02%
713,811
-6,181
-0.9% -$281K
VRNA
3
DELISTED
Verona Pharma
VRNA
$33.9M 6.25%
358,297
-187,575
-34% -$13.9M
URGN icon
4
UroGen Pharma
URGN
$2.14B
$27.7M 5.11%
2,022,482
+641,324
+46% +$6.15M
RYTM icon
5
Rhythm Pharmaceuticals
RYTM
$7.01B
$25.3M 4.67%
400,772
+63,167
+19% +$3.87M
INSM icon
6
Insmed
INSM
$27.3B
$25.1M 4.62%
249,060
-72,306
-22% -$5.53M
KALV
7
DELISTED
KalVista Pharmaceuticals
KALV
$20.7M 3.82%
1,832,171
+133,187
+8% +$1.63M
NBIX icon
8
Neurocrine Biosciences
NBIX
$15.8B
$20.5M 3.78%
162,969
+90,386
+125% +$10.4M
MRUS
9
CALL
DELISTED
Merus
MRUS
$20.1M 3.71%
+382,500
New +$18M
ETNB
10
DELISTED
89bio
ETNB
$20M 3.69%
2,037,087
+526,589
+35% +$4.36M
ORIC icon
11
Oric Pharmaceuticals
ORIC
$1.31B
$18.3M 3.37%
1,800,829
-259,411
-13% -$1.74M
NUVL
12
DELISTED
Nuvalent
NUVL
$18M 3.31%
235,583
-203,435
-46% -$14.9M
SLNO
13
DELISTED
Soleno Therapeutics
SLNO
$17.1M 3.16%
204,591
+38,174
+23% +$2.86M
XNTK icon
14
CALL
State Street SPDR NYSE Technology ETF
XNTK
$1.91B
$16.6M 3.06%
+200,000
New +$41.5M
ASND icon
15
Ascendis Pharma A/S
ASND
$17.7B
$14.9M 2.75%
86,552
+10,801
+14% +$1.76M
CGON icon
16
CG Oncology
CGON
$6.51B
$14.1M 2.59%
+541,034
New +$13M
VCYT icon
17
Veracyte
VCYT
$3.41B
$12.1M 2.24%
448,495
-185,337
-29% -$5.37M
SRRK icon
18
Scholar Rock
SRRK
$6.99B
$12.1M 2.23%
+341,010
New +$10.7M
RNAM
19
DELISTED
Avidity Biosciences
RNAM
$11.6M 2.15%
410,000
-1,312
-0.3% -$39.1K
PCVX icon
20
Vaxcyte
PCVX
$8.98B
$9.36M 1.73%
+287,796
New +$9.43M
PFE icon
21
Pfizer
PFE
$158B
$8.35M 1.54%
+344,338
New +$8.03M
NUVL
22
CALL
DELISTED
Nuvalent
NUVL
$7.65M 1.41%
+100,200
New +$7.33M
BBOT
23
BridgeBio Oncology
BBOT
$710M
$6.51M 1.2%
613,393
– –
GOSS icon
24
Gossamer Bio
GOSS
$87.9M
$6.33M 1.17%
5,146,782
-1,173,902
-19% -$1.28M
MTSR
25
DELISTED
Metsera Inc
MTSR
$5.91M 1.09%
207,581
+94,822
+84% +$2.35M
1
2 3 4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Silverarc Capital Management held 88 positions worth $542M, up 11% from $489M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Silverarc Capital Management withdrew a net $63.4M in Q2 2025, closing 23 positions and reducing 25 holdings. Its most notable exit was Disc Medicine, an estimated $11.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, Silverarc Capital Management opened a new position in CG Oncology worth $14.1M.

  • Silverarc Capital Management's largest Q2 2025 buy was CG Oncology: 541,034 shares worth $14.1M.
  • Silverarc Capital Management added most to Neurocrine Biosciences in Q2 2025, an estimated $10.4M increase.
  • Silverarc Capital Management's biggest Q2 2025 reduction was Nuvalent, cutting an estimated $14.9M.
  • Silverarc Capital Management fully exited Disc Medicine in Q2 2025, selling an estimated $11.7M.
  • Silverarc Capital Management's ten largest holdings make up 50% of its $542M portfolio in Q2 2025.
  • Silverarc Capital Management opened 19 new positions and closed 23 in Q2 2025.
  • Silverarc Capital Management's portfolio value rose 11% quarter-over-quarter to $542M.

Based on Silverarc Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.